Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues

被引:113
作者
Cunha, Ana C. [1 ]
Weigle, Bernd [1 ]
Kiessling, Andrea [1 ]
Bachmann, Michael [1 ]
Rieber, E. Peter [1 ]
机构
[1] Tech Univ Dresden, Fac Med, Inst Immunol, D-01307 Dresden, Germany
关键词
prostate cancer; T cell-based immunotherapy; tissue-specific antigen; quantitative real-time PCR;
D O I
10.1016/j.canlet.2005.05.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of immune defense mechanisms against tumor antigens appears to be a promising therapeutic option for advanced prostate cancer (PCa). Specific immunotherapy critically depends on target antigens that are selectively expressed in the tumorous and optional in the normal prostate tissue in sufficient amounts. Although several prostate antigens have been described and some have already been used in clinical trials, a detailed comparative evaluation of their tissue-specificity and expression levels is still lacking. We determined the transcript levels of eight prostate targets (PSA, PAP, PSCA, PSGR, Prostein, PSMA, AIbZIP, trp-p8) in 16 different tissues by quantitative PCR and calculated a tissue-specificity index (TSI) for each molecule. Besides a preferential expression in prostate for all targets, striking differences in the expression levels and TSI were revealed which may be important for the selection of appropriate antigens for immunotherapy of PCa. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:229 / 238
页数:10
相关论文
共 44 条
[1]  
Banchereau J, 2001, CANCER RES, V61, P6451
[2]   Prostate-specificy-antigen testing for early diagnosis of prostate cancer. [J].
Barry, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (18) :1373-1377
[3]   Cancer immunotherapy: A treatment for the masses [J].
Blattman, JN ;
Greenberg, PD .
SCIENCE, 2004, 305 (5681) :200-205
[4]  
Burch PA, 2000, CLIN CANCER RES, V6, P2175
[5]   Improving the efficacy of antibody-based cancer therapies [J].
Carter, P .
NATURE REVIEWS CANCER, 2001, 1 (02) :118-129
[6]  
CHU TM, 1978, INVEST UROL, V15, P319
[7]  
Correale P, 1998, J IMMUNOL, V161, P3186
[8]  
Dannull J, 2000, CANCER RES, V60, P5522
[9]   Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy [J].
Fong, L ;
Brockstedt, D ;
Benike, C ;
Breen, JK ;
Strang, G ;
Ruegg, CL ;
Engleman, EG .
JOURNAL OF IMMUNOLOGY, 2001, 167 (12) :7150-7156
[10]   Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate [J].
Friedman, RS ;
Spies, AG ;
Kalos, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (04) :1091-1101